Merck is in talks to buy cancer drug developer Revolution Medicines in a $28 billion to $32 billion deal, the Financial Times ...

DARMSTADT, Germany--(BUSINESS WIRE)--Merck, a leading science and technology company, and Siemens, a leading technology company, signed a new Memorandum of Understanding (MoU), extending their ...

Merck & Co. Inc., (NYSE:MRK) is one of the best conservative stocks to buy now. On September 23, the company confirmed a strategic collaboration with Variational AI to leverage its Enki Platform in ...

FRANKFURT (Reuters) -Germany's Merck KGaA on Thursday agreed to use Boston-based Valo Health's drug research services in a collaboration focused on Parkinson's and related diseases that is potentially ...

Blackstone Life Sciences agreed to give Merck $700 million to support its development of an investigational cancer drug called sacituzumab tirumotecan in exchange for low-to-mid-single-digit royalties ...

Merck is in talks to buy cancer drug developer Revolution Medicines in a deal that may be worth $28 billion to $32 billion ...

Merck & Co.'s peptides could be undergoing a transformation into oral tablets thanks to a $493 million licensing deal the company inked with Austria-based drug delivery technology maker Cyprumed.

Discover how early CMC, process optimization, and formulation strategy drive scalable, commercially viable drugs.

To optimize the final formulation for a drug, it must meet many criteria beyond producing a safe and effective product. For example, it must be stable and amenable to various manufacturing steps, such ...

Merck is expanding its pipeline and portfolio of cardio-pulmonary disease treatments by acquiring Verona Pharma plc. The Rahway pharma giant announced the deal for the biopharmaceutical company ...